Exkivity

Active Ingredient(s): Mobocertinib
FDA Approved: * September 15, 2021
Pharm Company: * TAKEDA PHARMS USA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Exkivity Overview

Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer.[2][3] The most common side effects include diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.[2] Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.[...

Read more Exkivity Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mobocertinib

Recent Exkivity Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Mobocertinib
  • Capsule: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Mobocertinib or a similar ingredient: (1 result)